Literature DB >> 2499428

The Lennox-Gastaut syndrome.

J Roger, C Dravet, M Bureau.   

Abstract

Entities:  

Mesh：

Year:  1989        PMID： 2499428     DOI： 10.3949/ccjm.56.s1.172

Source DB:  PubMed          Journal:  Cleve Clin J Med        ISSN： 0891-1150            Impact factor:   2.321


× No keyword cloud information.
  4 in total

1.  The cost effectiveness of rufinamide in the treatment of Lennox-Gastaut syndrome in the UK.

Authors:  Agnes Benedict; Lara Verdian; Grant Maclaine
Journal:  Pharmacoeconomics       Date:  2010       Impact factor: 4.981

2.  Treating Lennox-Gastaut syndrome in epileptic pediatric patients with third-generation rufinamide.

Authors:  Jessica Gresham; Lea S Eiland; Allison M Chung
Journal:  Neuropsychiatr Dis Treat       Date:  2010-10-05       Impact factor: 2.570

3.  Onset of action and seizure control in Lennox-Gaustaut syndrome: focus on rufinamide.

Authors:  Russell P Saneto; Gail D Anderson
Journal:  Ther Clin Risk Manag       Date:  2009-05-04       Impact factor: 2.423

4.  Treatment of Lennox-Gastaut syndrome: overview and recent findings.

Authors:  Kenou van Rijckevorsel
Journal:  Neuropsychiatr Dis Treat       Date:  2008-12       Impact factor: 2.570
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.